Photocure Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
102
- Stock Symbol
-
PHO
- Investments
-
1
- Share Price
-
$4.48
- (As of Friday Closing)
Photocure General Information
Description
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
Contact Information
Website
www.photocure.comCorporate Office
- Hoffsveien 4
- 0275 Oslo
- Norway
Corporate Office
- Hoffsveien 4
- 0275 Oslo
- Norway
Photocure Stock Performance
As of 13-Nov-2026, Photocure’s stock price is $4.48. Its current market cap is $121M with 27M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.48 | $4.38 | $4.34 - $8.24 | $121M | 27M | 73.8K | $0.19 |
Photocure Financials Summary
As of 30-Sep-2026, Photocure has a trailing 12-month revenue of $70.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 124,081 | 164,461 | 122,314 | 154,106 |
| Revenue | 70,600 | 51,183 | 48,739 | 47,266 |
| EBITDA | 13,636 | 2,424 | 4,857 | 4,913 |
| Net Income | 5,006 | (146) | (310) | 92 |
| Total Assets | 91,564 | 70,262 | 65,189 | 70,004 |
| Total Debt | 0 | 1,029 | 2,332 | 2,752 |
Photocure Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Photocure Comparisons
Industry
Financing
Details
Photocure Competitors (4)
One of Photocure’s 4 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom |
Photocure Patents
Photocure Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026052815-A1 | Use of hal in a method for predicting bladder cancer immunotherapy response | Pending | 05-Sep-2024 | ||
| EP-4804913-A1 | Method and system for automated guided laser coagulation | Pending | 09-Nov-2023 | ||
| WO-2025099327-A1 | Method and system for automated guided laser coagulation | Inactive | 09-Nov-2023 | ||
| AU-2024231397-A1 | Therapy for bladder cancer | Pending | 07-Mar-2023 | ||
| EP-4676462-A1 | Therapy for bladder cancer | Pending | 07-Mar-2023 | A61K31/221 |
Photocure Signals
Photocure Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Photocure Acquisitions (1)
Photocure’s most recent deal was a Merger/Acquisition with Vesica Health for . The deal was made on 01-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vesica Health | 01-Jun-2026 | Merger/Acquisition | Diagnostic Equipment |
Photocure ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
27.14 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Pharmaceuticals
Subindustry
of 438
Rank
Percentile
Photocure Exits (1)
Photocure’s most recent exit was on 01-Jun-2026 from Vesica Health. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Vesica Health | 01-Jun-2026 | Completed |
|
Photocure Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vesica Health | Princeton, NJ | 2022 |
Photocure FAQs
-
When was Photocure founded?
Photocure was founded in 1997.
-
Where is Photocure headquartered?
Photocure is headquartered in Oslo, Norway.
-
What is the size of Photocure?
Photocure has 102 total employees.
-
What industry is Photocure in?
Photocure’s primary industry is Pharmaceuticals.
-
Is Photocure a private or public company?
Photocure is a Public company.
-
What is Photocure’s stock symbol?
The ticker symbol for Photocure is PHO.
-
What is the current stock price of Photocure?
As of 13-Nov-2026 the stock price of Photocure is $4.48.
-
What is the current market cap of Photocure?
The current market capitalization of Photocure is $121M.
-
What is Photocure’s current revenue?
The trailing twelve month revenue for Photocure is $70.6M.
-
Who are Photocure’s competitors?
Novartis, Evonile Pharma, Sanofi, and AstraZeneca are competitors of Photocure.
-
What is Photocure’s annual earnings per share (EPS)?
Photocure’s EPS for 12 months was $0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process